Citation(s)
- Chen L, Xing X, Lei M, Liu J, Shi Y, Li P, Qin G, Li C, Li Y, Wang Q, Gao T, Hu L, Wang Y, Yang W
Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose-lowering drugs: a subgroup a
- El Naggar NK, Soewondo P, Khamseh ME, Chen JW, Haddad J
Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: results from the A1chieve study
- El-Naggar N, Almansari A, Khudada K, Salman S, Mariswamy N, Abdelfattah W, Hashim F
The A1 chieve study - an observational non-interventional study of patients with type 2 diabetes mellitus initiating or switched to insulin analogue therapy: subgroup ana
- Home P, Naggar NE, Khamseh M, Gonzalez-Galvez G, Shen C, Chakkarwar P, Wenying Y
An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: the A1chieve study. Diabetes Res
- Home PD, Latif ZA, González-Gálvez G, Prusty V, Hussein Z
The effectiveness and safety of beginning insulin aspart together with basal insulin in people with type 2 diabetes in non-Western nations: results from the A1chieve observational study. Diabetes
- Home PD, Shen C, Hasan MI, Latif ZA, Chen JW, González Gálvez G
Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs. Diabetes Care. 2014;37(5):1237-45. doi:
- Hwang YC, Kang JG, Ahn KJ, Cha BS, Ihm SH, Lee S, Kim M, Lee BW
The glycemic efficacies of insulin analogue regimens according to baseline glycemic status in Korean patients with type 2 diabetes: sub-analysis from the A(1)chieve(®) study. Int J Clin Prac
- Khamseh ME, Haddad J, Yang W, Zilov A, Bech OM, Hasan MI
Safety and effectiveness of biphasic insulin aspart 30 in different age-groups: a1chieve sub-analysis. Diabetes Ther. 2013 Dec;4(2):347-61. doi: 10.1007/s13300-013-0033-z.
- Litwak L, Goh SY, Hussein Z, Malek R, Prusty V, Khamseh ME
Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study. Diabetol Metab Syndr. 2013 Oct
- Randeree H, Liebl A, Hajjaji I, Khamseh M, Zajdenverg L, Chen JW, Haddad J
Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: a1chieve sub-analysis. Diabetes Ther. 2013 Jun;4(1):153-66. doi: 10.1007/s13300-013-0026-y.
- Shah S, Yang W, Hasan MI, Malek R, Molskov Bech O, Home P
Biphasic insulin aspart 30 in insulin-naive people with type 2 diabetes in non-western nations: results from a regional comparative multinational observational study (A(1)chieve). Diabetes Technol
- Shah S, Zilov A, Malek R, Soewondo P, Bech O, Litwak L
Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: results from the A1chieve observational study. Diabetes Res Clin Pract. 2011 Dec;94(3):364-7
- Shah SN, Litwak L, Haddad J, Chakkarwar PN, Hajjaji I
The A1chieve study: a 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice. Diabetes Res Clin Pract. 2010 May;88 Suppl 1
- Yang W, Zhuang X, Li Y, Wang Q, Bian R, Shen J, Hammerby E, Yang L
Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A1chieve® observational study. Health Qual Life Outcomes.
- Zilov A, El Naggar N, Shah S, Shen C, Haddad J
Insulin detemir in the management of type 2 diabetes in non-Western countries: safety and effectiveness data from the A1chieve observational study. Diabetes Res Clin Pract. 2013 Sep;101(3):317-25. doi: 10.10
The Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or in Combination) in Subjects With Type 2 Diabetes Previously Treated With Other Anti-diabetic Medication. A 24-week, International, Prospective, Multi-centre, Open-labelled, Non-interventional Study
Details for clinical trial NCT00869908
